TP53 and non-small cell lung carcinoma: Hot spot mutations analysis in serial cfDNA samples from the Lithuanian NSCLC patient cohort confirmed the clinical value of TP53 mutation and overall cfDNA mutational burden as a sensitive biomarker of the disease progression.